Document Detail

Complementary mechanisms of action and rationale for the fixed combination of perindopril and indapamide in treating hypertension - update on clinical utility.
MedLine Citation:
PMID:  21949617     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Although reducing blood pressure is the most important approach to reduce cardiovascular outcomes in the hypertensive population, the majority of patients fail to attain the targets. Most patients with hypertension need at least 2 antihypertensive agents to achieve blood pressure goals. The 2007 European hypertension guidelines state that combined therapy is needed when monotherapy does not attain blood pressure objectives and as a first-line treatment in high-risk patients. This point has been reinforced in the 2009 update of the European guidelines. The advantages of combination therapy are well documented with the potential for increased antihypertensive efficacy as a result of different mechanisms of action, and a lower incidence of adverse effects because of the lower doses used and the possible compensatory responses. Moreover, the use of fixed dose combinations are specially recommended as they facilitate treatment compliance. The inhibition of the renin-angiotensin system appears to be very beneficial in the treatment of patients with hypertension along the cardiovascular continuum and the combination of a renin-angiotensin system inhibitor and a diuretic is particularly recommended. Many clinical trials have demonstrated the benefits of the fixed combination perindopril/indapamide in the treatment of hypertension. The aim of this manuscript is to update the published data on the efficacy and safety of this fixed combination.
Vivencio Barrios; Carlos Escobar
Related Documents :
21721987 - Association of stroke with ambulatory arterial stiffness index (aasi) in hypertensive p...
21896147 - Renin inhibitors.
881387 - Difference between the he bolus and n2 technique for measuring closing volume.
21876967 - A sigmoidal fit for pressure-volume curves of idiopathic pulmonary fibrosis patients on...
16162417 - Ultrasonic control of ceramic membrane fouling by particles: effect of ultrasonic factors.
6409447 - Myocardial salvage by intravenous nitroglycerin in conscious dogs: loss of beneficial e...
Publication Detail:
Type:  Journal Article     Date:  2010-05-10
Journal Detail:
Title:  Integrated blood pressure control     Volume:  3     ISSN:  1178-7104     ISO Abbreviation:  Integr Blood Press Control     Publication Date:  2010  
Date Detail:
Created Date:  2011-09-28     Completed Date:  2011-11-10     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  101562709     Medline TA:  Integr Blood Press Control     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  11-9     Citation Subset:  -    
Department of Cardiology, Hospital Ramon y Cajal, Madrid, Spain;
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  De-stiffening drug therapy and blood pressure control.
Next Document:  Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or i...